Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673598 | 0.86 | L3MBTL1 (0.55) | PREPHPGD | |
| SCHEMBL5672334 | 0.83 | KMT2A (0.50) | PREPHPGD | |
| SCHEMBL5672214 | 0.82 | PREP (0.58) | PREP | |
| SCHEMBL2911206 | 0.77 | CHRNA7 (0.58) | — | |
| Hydrochloric Acid SCHEMBL2908231 | 0.76 | CHRNA7 (0.57) | — | |
| SCHEMBL7556010 | 0.74 | CHRNA7 (0.71) | — | |
| SCHEMBL5673611 | 0.74 | CHRM1 (0.47) | PREPCHRM1HPGD | |
| SCHEMBL6140096 | 0.73 | CHRNA7 (0.44) | CYP2C9CYP2C19 | |
| SCHEMBL3248601 | 0.73 | NPC1 (0.64) | HPGDGAA | |
| SCHEMBL6140099 | 0.73 | CHRNA7 (0.44) | CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001902-B2 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof | SANOTL-AVENTIS (FR) | 2006-02-21 | — | — | US | disclosed |
| EP-1289987-B1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-05-19 | — | — | EP | disclosed |
| US-20040029884-A1 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof | SANOFI (FR) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029884-A1 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof | CBR1, FPR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PREP 2755/4885CHRM1 447/4885CYP2C9 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.